Form 4: Agilon Health Director Jeffrey A. Schwaneke Reports Acquisition and Disposal of Common Stock

Director Jeffrey A. Schwaneke reports acquiring 32,119 shares of Agilon Health common stock and disposing of an unspecified amount on May 29, 2024.

Summary

• On May 29, 2024, Jeffrey A. Schwaneke, a director of Agilon Health, Inc. (AGL), acquired 32,119 shares of common stock.
• The acquisition was through restricted stock units that vest fully on May 29, 2025, contingent upon continued service as a director.
• The price of the acquired shares was $0.
• Schwaneke also disposed of an unspecified amount of common stock on the same day.
• Following these transactions, Schwaneke beneficially owns 64,050 shares, including restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The acquisition of shares by a director is generally positive, but the simultaneous disposal tempers this view. The overall impact is likely minimal.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future.

Negatives

• The disposal of an unspecified amount of shares by the director could be interpreted negatively, although the reason for disposal is not provided.

Risks

• The vesting of the restricted stock units is contingent upon continued service as a director, which introduces a dependency on Schwaneke's continued involvement with the company.

Future Outlook

The vesting of the restricted stock units on May 29, 2025, is contingent upon continued service as a director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• Shareholders may view the director's stock transactions as a signal of confidence or concern, depending on their interpretation of the acquisition and disposal.

Key Dates